Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Total Liabilities data on file, last reported at $204.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $204.7 million, down 8.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $204.7 million (down 8.45% YoY), and the FY2025 annual result was $210.2 million, down 7.71% from the prior year.
• Total Liabilities fell to $204.7 million in Q1 2026 per RYTM's latest filing, from $210.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $239.2 million in Q2 2025 and troughed at $49.1 million in Q1 2022.
• A 5-year average of $168.1 million and a median of $197.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities surged 223.06% in 2022, then slipped 8.45% in 2026.
• A 5-year view of Total Liabilities shows it stood at $118.2 million in 2022, then soared by 37.87% to $163.0 million in 2023, then soared by 39.72% to $227.7 million in 2024, then fell by 7.71% to $210.2 million in 2025, then dropped by 2.6% to $204.7 million in 2026.
• Business Quant data shows RYTM's Total Liabilities at $204.7 million in Q1 2026, $210.2 million in Q4 2025, and $211.2 million in Q3 2025.